Liquidia Corporation operates through subsidiaries Liquidia Technologies, Inc. and RareGen, focusing on the development and commercialization of biopharmaceutical products using its PRINT technology. The company targets markets for treatments of pulmonary arterial hypertension (PAH) and related conditions.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.